



AXN| Aoxing Pharmaceuticals | Profile | Summary

Aoxing Pharmaceuticals (AXN) is a specialty pharmaceutical company engaged in research, development, manufacturing and distribution of a variety of narcotics and pain-management products.

Aoxing was Founded in 1655, more than 300 years of heritage and deep roots in traditional and contemporary Chinese medicine.

The company has China's largest research & development facility (over 300 acre campus) and most advanced manufacturing facility for highly regulated narcotic medicines. Over 500 employees are dedicated in research and development of drugs for pain management, neurological disorders and narcotics.

Its facility is one of the few GMP facilities licensed for the manufacture of highly regulated narcotic medicines by the China State Food and Drug Administration (SFDA). It has strategic alliance partnerships with global pharmaceutical companies like the UK's Johnson

Matthey

Plc

(LSE:

JMAT

),

QRx

Pharma

(

ASX

:

QRX

) of Australia and others.

Aoxing

is based in China and its US office is located in Jersey City, NJ.

Source: Aoxing Pharmaceuticals, [OxBridge Research](#), [Daily Stock Deals](#), [King. M](#), [OTC](#) [PS](#)

! Don't miss the NEXT premium Alert! Sign-up, Get Alerts, [MakeMoney](#) [®](#)

we received or expecting compensation from the featured

company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. com is an OxBridge affiliate/partner website.

Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by Ox

Bridge
and/or its affiliates.

OxBridge

Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only.

OxBridge

urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment from the company/a third party/shareholder.

We receive compensation from companies for providing various IR

services, including publication, advertisement, and social media awareness, therefore our views/opinion are inherently biased.

Please read the full disclosure/disclaimer, if you need assistance contact

Editor@OxBridgeResearch.com

OxbridgeResearch.com , All Rights Reserved.
Trademarks/logos are of their respective owners.

It's YOUR money - Invest WISELY™